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Abstract: Cancer pain is often difficult to treat. Growing evidence indicates that chemical 
mediators secreted by the tumor itself play an important role in the development of cancer pain. 
One such mediator, endothelin-1 (ET-1) is secreted by different tumor types. Studies have 
indicated that ET-1 induces spontaneous and evoked nociception in rodents and in humans. The 
focus of all these studies has always been on a single administration of ET-1. Such an acute expo-
sure to ET-1 however bears little resemblance to the clinical condition in which cancer patients 
are exposed continuously for many months to increased levels of ET-1. To improve the knowledge 
of the pathological role of ET-1 in cancer, we developed an animal model of prolonged exposure 
to ET-1. Rats were exposed to subcutaneous administration of ET-1 for seven consecutive days, 
with a total amount of 67.4 nmol. On days +2, +3, +5, +7, and +10 sensitivity to von Frey hairs 
and to pin-prick stimulation were evaluated. Prolonged administration of ET-1 induced signs of 
mechanical allodynia on several time points. Although the administered doses were very small, 
prolonged administration of ET-1 seems to lead to a state of mechanical allodynia.
Keywords: endothelin-1, rat, chronic administration, von Frey hair, pin-prick, mechanical 
allodynia
Introduction
Pain associated with metastatic cancer is often debilitating and difficult to treat.1 Among 
all cancer patients, the prevalence of metastatic cancer pain may exceed 75%.2 These 
patients often require large systemic doses of analgesics (eg, opioids) that do not always 
provide complete pain relief and that frequently produce undesirable side effects. 
There is growing preclinical evidence that peripheral sensitization of nociceptors is 
involved in the generation and maintenance of cancer pain.3–5 Chemical mediators 
that are synthesized by either cancer cells or other cell types present in the tumor 
stroma, such as immune cells, may contribute to the lowering of nociceptor threshold 
of activation.6–8 One candidate mediator for lowering this threshold of activation is 
the potent vasoconstrictor peptide, endothelin-1 (ET-1), whose expression levels are 
high in several types of tumors.9–12
Most efforts to establish a pathological role of ET-1 have focused on its role in 
cardiovascular disease (for reviews see Sugden and Clerk,13 Shiffrin14). Recently, 
ET-1 has been recognized as a proalgesic mediator that is involved in the patho-
physiology of many different pain syndromes which range from inflammatory states, 
complex regional pain syndromes (CRPS), sickle cell disease to cancer.9,15–17 Further-
more, its nociceptive effects are independent from its vasoconstrictive effects.18 
Application of ET-1 has been shown to induce nociceptive behavior in rodents, and Journal of Pain Research 2009:2 68
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pain in humans.15,18–21 The results of clinical studies have 
shown the existence of a correlation between the severity of 
the pain and plasma levels of endothelins in patients with 
prostate cancer.22
Despite the abundance of preclinical reports, the 
experimental conditions of these studies often bear little 
resemblance with clinical pathological states. These experi-
ments usually use a single administration of ET-1, whereas in 
pathological conditions, such as cancer, patients have chroni-
cally (uninterrupted) elevated ET-1 levels in their plasma. 
The results of human studies have reported that mean plasma 
ET-1 levels in patients with different cancerous conditions 
are between 4–5 pg/mL.12,23–25 Although preclinical studies 
have applied very diverse concentrations of ET-1, these are 
probably consistently higher than the observed levels in 
human pathological conditions. Picomolar doses of injected 
ET-1 that yield very low local ET-1 concentrations are 
probably closer to the plasma levels of endogenous ET-1 that 
are found in human pathological conditions. It should be noted 
that tissue levels of ET-1 could well be extremely important 
for pain induction in cancer syndromes. ET-1 is indeed 
released from endothelial cells in a polarized fashion into 
the direction of surrounding vascular tissue and thus, plasma 
levels of  ET-1 are likely to be only a fraction of the levels in 
surrounding tissues and should perhaps be considered as a 
merely “spill over” from the tissue compartment.
Until now, only one study has investigated the nociceptive 
effects of repeated or prolonged administration of ET-1.26 
These investigators reported that repeated administration 
of low doses of ET-1 in rats led to the development of an 
acute desensitization period that persist for up to 24 hours. 
In the absence of confirming data, we decided to further 
investigate the effects of chronic delivery of exogenous 
ET-1 on spontaneous and evoked pain sensations in rats. The 
results of our preliminary experiments (unpublished data) 
revealed that prolonged perineural administration of ET-1 
quickly (within 24 hours) results in the development of an 
intense fibrotic reaction around the subcutaneous tip of 
the cannula. This fibrotic reaction can rapidly result in 
complete blockage of the cannula, thereby reducing its 
performance and preventing further delivery of ET-1. Based 
on these preliminary findings, we opted to use very low doses 
of ET-1 to avoid any confounding inflammatory response. 
The final dose of ET-1 was chosen in accordance with the 
results of previous ET-1-based behavioral studies.18,20,27,28
The present project was undertaken to further charac-
terize the exact role of ET-1 in nociception. To this end, we 
assessed the effect of prolonged administration of minute 
doses of ET-1 on the perception of mechanically evoked 
nociception.
Material and methods
experimental animals
Twenty male Sprague–Dawley rats (180–200 g at arrival, 
Charles River®) were used in this protocol. They were housed 
in pairs in conventional plastic cages (24 × 40 × 15 cm) in a 
rodent colony room whose room temperature was 21 ± 1 °C 
and a relative humidity of 45 ± 5%. Water and food were 
available ad libitum. Rats were kept under a reversed 12:12 
hour dark/light cycle (lights on at 20:00 hours) and were 
acclimated for at least three weeks to the housing conditions 
before testing. The rats were habituated to the test procedure 
(see later for detailed description) three times before base-
line values were obtained. The experimental protocol was 
approved by the Animal Ethical Committee of the University 
of Antwerp, and the experiments were performed in accor-
dance with the Directives of European Community Council 
on the use and care of laboratory animals.
experimental groups and drug 
administration
Rats were randomly assigned into two groups. Group 1 
received ET-1 and group 2 received saline. Rats were 
implanted with an osmotic pump delivering either ET-1 
(24 µg/day) or saline. The total amount of ET-1 admin-
istered to the rats over seven days was 67.4 nmol. ET-1 
solution was prepared by dissolving the dry compound in 
saline. Preliminary testing has confirmed the stability of the 
ET-1 solution in these pumps. Additionally, samples of the 
ET-1 solution, after being contained in the osmotic pumps 
during seven consecutive days, were afterwards injected 
into the rat’s paw to check any remaining biological activity. 
Indeed, such injections induced the previously described 
paw-flinching syndrome, evidencing a remaining biological 
(nociceptive) activity of this ET-1 solution. Pumps (Alzet 
2ML1) were filled by injecting the solution into the pumps 
using a 1 ml sterile syringe and a specialized blunt needle. 
These pumps have a nominal pumping rate of 10.0 µl/hr 
and a nominal duration of seven days. In order to obtain 
immediate pumping after implantation, the pumps were 
primed before implantation, according to the guidelines 
provided by the manufacturer. The pumps were prefilled in 
the usual manner and placed in sterile 0.9% saline at 37 °C 
overnight. During this priming period the catheter was 
draped outside the beaker to avoid any mixing of solutions. Journal of Pain Research 2009:2 69
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The next morning the pump was removed from the saline 
and implanted immediately.
The pumps were implanted into the rats under anesthesia. 
To this end, the rats were placed in a chamber containing 
4% isoflurane. When the rats lost consciousness, they were 
removed from the chamber, and anesthesia was maintained 
by 2.5% isoflurane delivered by a face mask. The dorsal 
area was shaved and then disinfected with Hibitane® 
(chlorhexidine 0.5% dissolved in 70% alcohol). A skin 
incision of approximately 2 cm made at the distal end of 
the scapula and a small subcutaneous pocket was created 
using hemostatic forceps. Ampicillin (0.1 ml of Pentrexyl®, 
Na ampicillin 1 g) was then injected into the pocket and the 
pump was inserted with its opening facing towards the back 
of the rat and away from the incision site (tip of the catheter 
pointing towards the lumbar region of the rat). Finally, the 
incision was closed with stainless steel staples (Disposable 
skin stapler with auto-release Appose 35 Regular; Sherwood–
Davis and Geck, St. Louis, MO, USA). After seven days the 
pumps were removed under general anesthesia.
In order to observe possible hemodynamic effects of the 
injected ET-1, systolic blood pressure was measured non-
invasively in all animals daily by tail cuff plethysmography 
(Letica 5100; PanLab, Barcelona, Spain). Blood pressure 
monitoring was performed according to standard procedures, 
described previously.29 Additionally, body weight was 
measured daily. Other clinical signs of distress were also 
followed, such as the appearance of red tears.
Behavioral testing
Rats were individually transported from the colony room to 
the test room (15 sec trip) in a covered plastic cage without 
bedding (24 (l) × 14 (w) × 17 (h) cm). von Frey and pin-
prick testing were conducted in a darkened room in which 
light was provided by a 60W red light bulb suspended 1 m 
above the test area and with a 45 dB background noise that 
was sufficient to decrease the interference of sudden external 
auditory stimuli. Testing of evoked behavior was always 
performed at the same moment, more precisely during late 
morning. An extensive training phase for the rats was per-
formed, in order to obtain highly reproducible results. All 
rats were as such acclimated to the testing conditions (ie, 
manipulation and transportation of the rats, stay in the dark-
ened room and in the test box, performance of mechanical 
testing, procedure of blood pressure measurement) during 
10 days before the start of the actual experiment. Baseline 
data were obtained one day before pump implantation. Fur-
ther data were obtained on post-implantation days +2, +3, 
+5, +7, and +10. Data that were collected on the tenth day 
were at approximately three days after the end of pump 
infusion and the removal of the pump. Behavioral testing 
was performed by the same examiner, who was blinded with 
respect to administration of ET-1 or saline. The code was 
broken after data entry and analysis.
Local cutaneous sensitivity
Responsiveness to mechanical stimulation of a dorsal area, 
approximately 25 mm caudal to the opening of the sub-
cutaneous pump, was measured using a series of three 
von Frey filaments (Stoelting Co, Wood Dale, IL, USA): 
2.150 g, 7.370 g, and 46.540 g and a pin-prick (21 gauge 
needle bent at a 45° angle). The cages of the rats were 
placed next to each other on a table and the experimenter 
sat in front of them. The scoring system used was adapted 
from Vos and colleagues30,31 to evaluate the reaction of 
the rats to the stimulation, and we have used this modified 
method previously in different behavioral and pharmaco-
logical studies.32–35 The response of an animal is analyzed 
according to different response categories: 0: no response, 
1: detection, 2: withdrawal reaction, 3: escape/attack. Lower 
scores indicate a weak responsiveness to stimulation while 
higher scores indicate a strong responsiveness. Under normal 
conditions (nonoperated rats and in absence of sensitivity 
modifying drugs) rats will display mechanical sensory 
thresholds ranging from 0 (no response at all to stimulation) 
to 1 (detective response) to the above mentioned mechanical 
stimulations in this particular skin region. These mechanical 
stimulations should therefore be considered as absolutely 
nonpainful in nonpathological conditions. In order not to 
sensitize the animals too much by performing too many 
manipulations and (mechanical) stimulations we decided 
not to include stimulation of distal dermatomes into the 
current study protocol.
statistical analysis
All statistical analyses were performed using SPSS for Mac 
(version 13.0.0; SPSS Inc., Chicago, IL, USA). In order 
to analyze data from mechanical stimulation, preliminary 
Kruskal–Wallis testing was performed in order to detect any 
time- or treatment-dependent differences between the different 
experimental groups. Comparisons between responses to 
mechanical stimulation (von Frey filaments and pin-prick) 
between experimental groups on a single time point were 
performed using the Mann–Whitney test. Exact significance 
[2*(1-tailed sig.)] was hereby calculated. The parameters of 
systolic blood pressure in both experimental groups at the Journal of Pain Research 2009:2 70
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individual time points were compared using an unpaired 
t-test. The significance level for this study was set at 5%.
Results
Hemodynamic and distress monitoring
No rats displayed significant alterations in systolic blood 
pressure (SBP) during the course of the administration of 
ET-1 or saline. At the starting point of the experiment, 
SBPs of both experimental groups were comparable 
(108 ± 5 mmHg). Mean SBPs over seven days (during ET-1 
and placebo administration) were not significantly different 
in ET-1-treated rats compared with those in placebo-infused 
rats (114 ± 3 vs 111 ± 2 mmHg). ET-1 and placebo-treated 
animals displayed identical increases in body weight. No 
signs of distress were observed in any rats.
cutaneous sensitivity to mechanical 
stimulation
Chronic administration of low doses ET-1 led to changes 
in sensitivity to different types of mechanical stimulation. 
Stimulation with the smallest von Frey hair (2.150 g) did not 
induce significant changes in response scores compared to 
saline-treated rats (Figure 1A). However, stimulation with 
7.370 g von Frey filament (Figure 1B) led to significantly 
increased response scores on day 3 ( p  0.05). Stimula-
tion with the largest of the three von Frey hairs (46.540 g; 
Figure 1C) resulted in significantly higher response scores 
in ET-1-treated animals on days 3, 5, and 7 compared to the 
control animals stimulated with the identical hair ( p  0.05). 
Finally, behavioral responses to pin-prick stimulation 
(Figure 2) displayed a somewhat similar time course with 
significantly increased responsiveness in ET-1-treated rats 
on days 3 and 5 ( p  0.05). Saline-treated animals displayed 
some changes in responsiveness to mechanical stimulation 
following the implantation of the pumps, but these changes 
always failed to reach statistical significance when compared 
to pre-implantation values ( p  0.05).
Discussion
To the best of our knowledge, the results of the present study 
constitute the first report on the effects on evoked nocicep-
tion of a prolonged local administration of endothelin-1 
(ET-1) in rats. ET-1-treated animals displayed significant 
changes in sensitivity to mechanical stimuli. Although 
the temporal changes in evoked behavior were somewhat 
different for the various intensities of mechanical stimula-
tion, significant alterations occurred particularly from the 
third day of ET-1 administration. The observed mechanical 
allodynia (increased sensitivity to nonpainful mechanical 
stimulations) disappeared after discontinuation of ET-1 
administration.
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Figure 1 Time course of changes in response scores to (A) stimulation with 2.150 
g von Frey filament, (B) 7.370 g von Frey filament, and (C) 46.540 g von Frey fila-
ment. saline () or endothelin-1 (eT-1) () was administered for seven consecutive 
days (see box in graph c). The following response codes were applied: ‘no response’ 
(indicated by 0 in the X-axis of the graph), ‘detection’ (1), ‘withdrawal reaction’ (2), 
‘escape/attack’ (3). Data are expressed as median values ± interquartile range.   Asterisks 
indicate a significant difference in response scores between ET-1 administration and 
saline (Mann–Whitney U test; p  0.05).Journal of Pain Research 2009:2 71
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Rats receiving continuous administration of saline did 
display some changes in sensitivity to mechanical stimula-
tion during the treatment period. However, none of these 
changes ever reached statistical significance and this result 
indicates that the administration of saline does not lead to 
significant changes in mechanical sensitivity. In addition, this 
result also means that the subcutaneous infusion of a fluid 
without pharmacological activity over seven days did not 
lead to the development of hypersensitivity in these animals. 
However, the subcutaneous implantation of a pump induces 
some changes in sensitivity in the animals, without ever 
reaching any significancy. Additionally, it should be noted 
that these changes occurred immediately after implantation 
of the pump, whereas the ET-1-induced changes occurred at 
a somewhat later stage. This time difference in the onset of 
changes in cutaneous sensitivity points to a clear difference 
between pump-induced and ET-1-induced changes.
The rather limited extent of changes in mechanical sensi-
tivity that was observed in the ET-1-treated animals is prob-
ably due to the low doses of ET-1 used in this investigation. 
The administration of 24 µg ET-1 per day corresponds to 
9.6 nmol per day (or a total of 67.4 nmol over seven days). 
This means that only about 6 pmol of ET-1 was released 
subcutaneously each minute. Previous studies investigating 
the algesic effects of ET-1 have involved different methods 
of administering ET-1. These methods range from injecting 
120 pmol ET-1 into the knee joint of rats,36 to application 
of 16 nmol ET-1 onto the epineurial surface of the sciatic 
nerve of a rat.18 The results of a recent study have shown that 
single injection of 0.1 nmol of ET-1 into the rat hind paw can 
induce sensitization of the ipsilateral paw to tactile stimula-
tion by von Frey hairs.37 In our study, approximately 50% of 
this dose was delivered each minute by the subcutaneously 
implanted osmotic pump. Considering the results obtained 
from previously published dosing regimens of ET-1, it is 
quite remarkable that such a low dose of ET-1 used in our 
study indeed induces a prolonged state of mechanical hyper-
algesia. This result implies that a continuous administration 
of ET-1 slowly leads to hypersensitivity, hereby providing 
an explanation for the onset of mechanical hyperalgesia after 
the third day of low dose ET-1 administration.
The experimental model used in our investigation reflects 
more accurately those clinical conditions in which patients 
are continuously exposed during weeks to months to elevated 
levels of ET-1. Nevertheless, some methodological limitations 
should certainly be considered. Animals were subjected to 
repeated mechanical stimulations that by itself could lead to 
some kind of hypersensitivity phenomenon. However, similar 
testing protocols have been used in our laboratory using other 
compounds and we found that the experimental protocols do 
not result in decreased thresholds.33,35 In addition, it would 
have been desirable to include additional testing for thermal 
sensitivity into the study protocol. However, this would have 
subjected the rats to even more testing manipulations on the 
same day, possible leading to a general state of sensitization 
and seriously jeopardizing the validity of the behavioral 
results. Because few data are currently available regarding 
the ET-1 concentrations that are present in cancerous tissues, 
the exact physiological relevance of the amounts of ET-1 that 
were applied in this protocol can not be correctly evaluated. 
It would have been interesting to combine the parameters 
of evoked sensation with measurements of (plasma/tissue) 
ET-1-concentration. This was not done in this protocol due 
to the technical difficulties linked to measurements of ET-1 
levels. Additionally, repetitive blood sampling would have 
greatly increased the stress for the animals. In future experi-
ments we plan to use enzyme-linked immunosorbent assays 
to obtain ET-1 measurements in plasma and tissue. Finally, 
we opted not to use a cancer pain model, in order to exclude 
any possible confounding factors due to the presence of a 
growing tumor. Studies using different cancer pain models 
have already shown the development of reduced thresholds 
to mechanical stimulation, as well as pain reduction after 
administration of ET-1 antagonists.38–40 However, a growing 
tumor mass will result in many pathophysiological changes 
in the rodents, hereby possibly confounding the nociceptive 
effects of ET-1.
Pre Day 2 Day 3 Day 5 Day 7 Day 10
0
1
2
3 *        *
ET-1 Administration
Time Points
R
e
s
p
o
n
s
e
 
s
c
o
r
e
s
(
M
e
d
i
a
n
 
±
 
I
n
t
e
r
q
u
a
r
t
i
l
e
 
R
a
n
g
e
)
Figure 2 effects of endothelin-1 (eT-1) administration on the reaction to a pin-prick 
(21 gauge needle). saline () or eT-1 () was administered for seven consecutive days 
(see box). The following response scores were applied: ‘no response’ (indicated by 
0 in the X-axis of the graph), ‘detection’ (1), ‘withdrawal reaction’ (2), ‘escape/attack’ 
(3). Data are expressed as median values ± interquartile range. Asterisks indicate a 
significant difference between ET-1 and saline administration (Mann–Whitney U test; 
p  0.05).Journal of Pain Research 2009:2 72
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Conclusion
This report is the first description of the neurosensory changes 
that develop following prolonged administration of ET-1. 
Although the administered doses were very small, prolonged 
administration of ET-1 seems to lead to a state of mechanical 
and heat hyperalgesia. This ET-1-based animal model could 
prove to be of great value for future investigations into the 
pathophysiology of ET-1-induced pain syndromes because 
the model, more closely mimics human clinicopathological 
conditions. Further studies are warranted to establish a dose-
response relationship of chronic delivery of ET-1 and to 
evaluate the effects of longer administration periods as well 
as different routes of administration. Finally, the differential 
effects of chronic administration of ET-1 on spontaneous 
behavior and evoked nociception should be carefully inves-
tigated in future experiments.
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